The PAR-1 antagonist vorapaxar inhibited the release of pro-inflammatory mediators from cultured keratinocytes, while PAR-1−/− mice that overexpress KLK6+ did not show the same level of psoriatic arthritis [63]. The gene discussed is KLK6; the disease is psoriatic arthritis.